Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biotech/Pharma Business
-
By Jason Derry — Amgen Inc. has announced that it will collaborate with Cytokinetics to generate small-molecule therapeutics for treating heart failure. In particular, the agreement relates to discovery, development, and commercialization of compounds that activate cardiac myosin. Cytokinetics has identified a particular cardiac myosin activator, CK-1827452, that is currently its lead drug…
-
By Jason Derry — Sigma-Aldrich has announced that it has agreed to give Pfizer a non-exclusive, worldwide license to use DNA-directed RNAi (ddRNAi) for research purposes. Sigma-Aldrich has an exclusive license to the ddRNAi technology (excluding the right to develop ddRNAi for therapeutic use in humans) from Benitec Ltd. and Australia's CSIRO (Commonwealth…
-
By Jason Derry — Crucell N.V. has announced a cross-licensing agreement with Merck & Co. relating to Crucell's vaccine technology. The deal allows Merck to use Crucell's technology in certain vaccine fields that have yet to be publicly disclosed, while Crucell will be able to manufacture its Advac®-based vaccines on a larger scale…
-
By Jason Derry — Nature Reviews Drug Discovery has published an article relating to potential pitfalls associated with licensing deals between pharmaceutical companies and biotechnology companies. In particular, the authors discuss the financial considerations of trying to in-license a biotech product in the early stages of clinical development. The article reviews strategies that…
-
By Jason Derry — Reliance Life Sciences has announced that it will buy a controlling share of GeneMedix Plc. UK-based GeneMedix is a biopharmaceutical company whose core technology involves "protein development scale-up and manufacture" (see link). Reliance Life Sciences, based in India, "is developing business opportunities in the domains of medical biotechnology, plant…
-
By Jason Derry — MedImmune, Inc. and Biowa, Inc. have announced a licensing and collaboration deal relating to development and commercialization of therapies for inflammatory diseases. In particular, the agreement relates to treatments that target interleukin-5 receptor. The companies have indicated that the initial focus will be on a monoclonal antibody, BIW-8405, which…
-
By Jason Derry — Alfacell Corp. and GENESIS Pharma S.A. have announced an exclusive licensing deal involving Alfacell's lead compound, ONCONASE®. The compound is in Phase IIIb clinical trials for the treatment of unresectable malignant mesothelioma. Under the agreement, GENESIS will receive the exclusive right to market and distribute ONCONASE® in Southeast Europe. Alfacell…
-
By Jason Derry — GlaxoSmithKline Plc. has announced a partnership with Genmab A/S relating to a particular antibody, HuMax-CD20, which is in late-stage clinical development for treating leukemia, lymphoma, and rheumatoid arthritis. Under the agreement, GSK will give Genmab an upfront payment of $103 million, and will purchase additional shares in the future,…
-
By Jason Derry — Exelixis Inc. has announced a collaboration agreement with Bristol-Myers Squibb that the companies hope will result in the discovery and eventual commercialization of compounds to treat cancer. Under the agreement, Exelixis will identify potential small molecule drugs candidates, and will carry the drugs through preclinical development. BMS will have…
-
By Jason Derry — In a press release published this morning, Eli Lilly and Co. has announced that it has raised its bid for Icos Corp. to $2.3 billion. The proposed deal will be considered by Icos shareholders in a meeting scheduled for December 26. According to its website, Icos is a biotechnology…
Patent Docs 